🔗 Share this article

While the US continues making sweeping changes to its vaccination guidelines, an unexpected name appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by casting doubt on Covid vaccines during the global health crisis and has focused upon potential deaths following Covid immunization in her recent time at the Food and Drug Administration.

Scheduled Shifts to Childhood Immunization Schedule

Health officials had intended to announce major changes to the pediatric vaccination calendar recently, synchronizing the US with the Danish vaccine program, sources say – a significant shift that would place the US at odds with much of the international standard with insufficient data for benefit. The planned update has been pushed back until the next year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to speak at the meeting. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the office this year.

A New Direction at the FDA

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Prasad solidify control at the FDA – and it points to a greater focus upon reevaluating previously authorized vaccines at the FDA.

Høeg has frequently advocated for discontinuing some pediatric vaccine recommendations in the US in order to be more like the Danish model, a nation with universal health coverage and a citizenry roughly the population of the state of Wisconsin.

So far public appearances, she has continued to focus on immunizations – traditionally the responsibility of Dr. Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Questions Over Background

Høeg has no obvious experience in drug development, regulation or leadership, which has been standard for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a major agency. She has no expertise in drug approvals.”

Previous commissioners of the center would “understand legal statutes and the underlying principles of pharmaceutical innovation”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that previous people who ran the center have had.”

CDER has an vast range of responsibilities at the FDA, Woodcock stated.

“Everybody just zeroes in on the new drug program, but the generic drug division approves thousands of generic drugs. There is also a biologic copycat branch, non-prescription drug unit and other areas, and each of these have to be managed,” she said. “The area you neglect, that’s the thing that I always told people is going to bite you.”

There is also, a significant management component to the position, which oversees more than 5,000 employees. “It is a huge leadership role, if you perform it correctly,” Woodcock said.

Response and Disputed Policies

When asked about concerns about Dr. Høeg's credentials and whether this assignment represents increased cooperation among regulatory chiefs on vaccines, a representative said that the “inquiries stem from inaccurate assumptions”.

“Her resume aligns with the functions of her role,” the official said, citing the time Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg takes over the commissioner’s recently launched expedited review system, a disputed rapid therapy clearance system that reportedly worried her preceding directors. “By what process are these medications being picked for this expedited pathway? Who makes the calls?” Dr. Howard questioned. “There is a lot of lack of transparency going on at the regulatory body right now.”

In general, he remarked, “the FDA seems to be moving towards laxer oversight of all drugs, aside from shots.”

Public Track Record on Vaccines

With vaccines, Dr. Høeg has a more documented, if problematic, past, some experts said. She published a study using unverified crowd-sourced reports to estimate the rate of heart inflammation after Covid immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are more dangerous than they are.

Among her “desired changes” for the new government encompassed altering rules for recently developed shots and discontinuing “unnecessary” vaccines, she said after the election on a online show. At the FDA, Høeg has reportedly proposed excluding adolescent males from receiving COVID-19 vaccines.

“She is an all-around true believer who starts off with her conclusions and works backwards to fit the data in a very disingenuous, dishonest manner,” Howard said.

Gaining Influence and a “Revenge Tour”

Høeg aligned with fellow skeptics, {like|